Mika Hosokawa

Dr. Mika Hosokawa


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
STShota Tanaka
Shota Tanaka
MHMika Hosokawa
Mika Hosokawa
ATAi Tatsumi
Ai Tatsumi
SAShiho Asaumi
Shiho Asaumi
RIRyoji Imai
Ryoji Imai
KOKenichi Ogawara
Kenichi Ogawara

22 May 2015 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MHMika Hosokawa
Mika Hosokawa
MSMai Saito
Mai Saito
ANAiko Nakano
Aiko Nakano
SISakura Iwashita
Sakura Iwashita
AIAyano Ishizaka
Ayano Ishizaka
SISeigo Iwakawa
Seigo Iwakawa
The aim of the present study was to determine the effects of long-term exposure of decitabine (DAC) to HCT116 colorectal cancer (CRC) cells on the acquisition of resistance to DAC as well as cross-resistance to anticancer drugs used for CRC or other epigenetic modifiers. In the present study, DAC-resistant HCT116 CRC cells were established through long-term treatment with increasing concentrations of DAC (10 to 540 nM); and the cross-resistance to other drugs was subsequently examined. DAC-resistant HCT116 cells were obtained following a 104-day treatment with DAC, including DAC-free intervals. The results demonstrated that the IC50 value of DAC was increased ~100-fold in DAC-resistant HCT116 cells. Messenger (m)RNA expression of secreted frizzed-related protein 1 (SFRP1), which is regulated by DNA methylation, was not detected in DAC-resistant cells; however, SFRP1 mRNA was present in HCT116 cells treated with DAC for 52 days. DNA methyltransferase 1 (DNMT1) protein levels were slightly decreased until day 81 and then returned to control levels in DAC-resistant cells. Further experiments using DAC-resistant HCT116 cells revealed that these cells exhibited cross-resistance to gemcitabine (Gem); however, cross-resistance was not observed for other DNMT inhibitors (azacitidine and zebularine), histone deacetylase inhibitors (trichostatin A, vorinostat and valproic acid) or anticancer drugs for CRC (5-fluorouracil, irinotecan and oxaliplatin). Furthermore, the protein expression levels of cytidine deaminase (CDA) were increased, while those of deoxycytidine kinase (dCK) were decreased in DAC-resistant HCT116 cells; by contrast, the mRNA expression levels for these proteins were not significantly altered. In conclusion, the results of the present study indicated that the long-term treatment of HCT116 cells with DAC led to the acquisition of resistance to both DAC and Gem. In addition, these results may be partly attributed to changes in CDA and/or dCK, which are involved in metabolic pathways common to these two drugs.

1 January 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MHMika Hosokawa
Mika Hosokawa
STShota Tanaka
Shota Tanaka
KUKumiko Ueda
Kumiko Ueda
SISeigo Iwakawa
Seigo Iwakawa
KOKen-Ichi Ogawara
Ken-Ichi Ogawara

1 November 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MHMika Hosokawa
Mika Hosokawa
RSRisako Seiki
Risako Seiki
SISeigo Iwakawa
Seigo Iwakawa
KOKen-Ichi Ogawara
Ken-Ichi Ogawara

14 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
YKYusuke Kono
Yusuke Kono
RKRenpei Kamino
Renpei Kamino
SHSoma Hirabayashi
Soma Hirabayashi
TKTakuya Kishimoto
Takuya Kishimoto
HKHimi Kanbara
Himi Kanbara
KOKenichi Ogawara
Kenichi Ogawara
Mesenchymal stem cells (MSCs) have a tumor-homing capacity; therefore, MSCs are a promising drug delivery carrier for cancer therapy. To maintain the viability and activity of MSCs, anti-cancer drugs are preferably loaded on the surface of MSCs, rather than directly introduced into MSCs. In this study, we attempted to load liposomes on the surface of MSCs by using the magnetic anionic liposome/atelocollagen complexes that we previously developed and assessed the characters of liposome-loaded MSCs as drug carriers. We observed that large-sized magnetic anionic liposome/atelocollagen complexes were abundantly associated with MSCs via electrostatic interactions under a magnetic field, and its cellular internalization was lower than that of the small-sized complexes. Moreover, the complexes with higher atelocollagen concentrations showed lower cellular internalization than the complexes with lower atelocollagen concentrations. Based on these results, we succeeded in the efficient loading of liposomes on the surface of MSCs by using large-sized magnetic anionic liposomes complexed with a high concentration of atelocollagen. The constructed liposome-loaded MSCs showed a comparable proliferation rate and differentiation potential to non-loaded MSCs. Furthermore, the liposome-loaded MSCs efficiently adhered to vascular endothelial cells and migrated toward the conditioned medium from cancer cells in vitro and solid tumor tissue in vivo. These findings suggest that liposome-loaded MSCs could serve as an efficient cell-based drug carrier for tumor-targeted delivery.

1 January 2017 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
STShota Tanaka
Shota Tanaka
MHMika Hosokawa
Mika Hosokawa
JMJyuri Matsumura
Jyuri Matsumura
EMEmi Matsubara
Emi Matsubara
AKAika Kobori
Aika Kobori
SISeigo Iwakawa
Seigo Iwakawa
The effects of zebularine, a DNA methyltransferase inhibitor, on the invasion activity as well as intracellular expression level of let-7b, tumor suppressor microRNA, were examined in three human colorectal cancer (CRC) cell lines: SW480, SW620, and oxaliplatin-resistant SW620 (SW620/OxR). Zebularine suppressed the invasion activity of SW620 and SW620/OxR cells. The intracellular expression level of let-7b was up-regulated by zebularine in SW620 and SW620/OxR cells. The overexpression of let-7b by the transfection of let-7b mimic suppressed invasion activity in SW620 and SW620/OxR cells. These results suggest that zebularine may inhibit invasion activity by up-regulating the intracellular expression level of let-7b in high-invasive CRC cells.